aad

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements seen across all six DLQI Domains indicating broad,…

2 days ago